Abstract
Background: Omalizumab is a recombinant humanized monoclonal antibody against immunoglobulin E (IgE) and is currently approved in the US for the treatment of moderate to severe allergic asthma and chronic idiopathic urticaria (CIU). Reports of off-label use of omalizumab for other IgE-related diseases including atopic dermatitis (AD) have been described with variable, and often conflicting, responses. Similar to other allergic disorders, AD patients may have elevated IgE levels, although levels can vary widely between patients (eg, <100 to over 1500 UI/ml).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
